Advertisement

MDRX

Veradigm Inc.

USD

Set alert

Price alert · MDRX

All alert types
4.74 USD +0.14 +3.04%
As of Feb 5, 2026
4.80 Day range 4.89
3.25 52-week range 6.00
YTD
-1.25%
1 year
+7.73%
Open
4.80
Prev close
4.60
Mkt cap
516.62M
Vol
9.96K
Avg vol
86.48K
EPS
-2.52
P/E
0.00
Div yield
0.00%
More statistics
Low
4.80
High
4.89
Forward P/E
6.52
Beta
0.70
Short ratio
3.92
Inst. own
106.79%
Dividend
0.00
Ex-div date
Oct 6, 2008
Earnings
Jan 4, 2024
50-d avg
9.22
200-d avg
11.81
1y target
15.00

2Y chart

Chart tools
Interval
MDRX two-year price chart3.005.207.409.6011.8Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
669.76M
Enterprise value
380.68M
Trailing P/E
7.13
Forward P/E
6.52
PEG ratio
-0.62
Price / sales
0.44
Price / book
0.57
EPS (TTM)
0.86
Beta
0.70
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
3.97%
Revenue (TTM)
1.53B
Revenue growth
5.00%
Free cash flow
155.57M
Total cash
492.60M
Total debt
218.81M
Return on equity
8.93%
Shares outstanding
109.26M
Short % of float
0.00%
50-day average
9.22
200-day average
11.81

Analyst view

Consensus: buy

Buy
Price target (mean) 15.00 +216.5% upside
Target (low)
10.00
Target (mean)
15.00
Target (high)
26.00
Ratings (0m) 20 12 buy · 7 hold · 1 sell
  • Strong buy6
  • Buy6
  • Hold7
  • Sell1
  • Strong sell0

Next earnings

Jan 4, 2024

Expected Jan 4, 2024. Consensus EPS estimate 0.27.

Earnings history

Financials — quick view

All financials
MDRX Revenue — quarterly 151.92M
2018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 2022
MDRX Net income — quarterly 14.53M
2018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 2022
MDRX EPS — quarterly 0.13
2018-Q4 20182019-Q1 20192019-Q2 20192019-Q3 20192019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 2022

Earnings

MDRX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 4, 2024Sep 1, 20230.22———
Oct 5, 2023Jun 1, 20230.20———
Jul 6, 2023Mar 1, 20230.14———
Nov 3, 2022Sep 1, 20220.190.23+0.04+21.05%
Aug 4, 2022Jun 1, 20220.160.18+0.02+12.50%
May 5, 2022Mar 1, 20220.200.13-0.07-35.00%

Upgrades / downgrades

MDRX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 9, 2023Stephens & Co.reitEqual-WeightEqual-Weight
Jul 5, 2023Argus ResearchdownBuyHold
Apr 11, 2023Stephens & Co.init—Equal-Weight
Jan 31, 2023Piper SandlerdownOverweightNeutral
Dec 6, 2022Argus ResearchupHoldBuy
Nov 17, 2022JP Morganmain—Underweight

About Veradigm Inc.

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Country
United States
Website
veradigm.com

News

Your note

Sign in to keep a note on MDRX — it syncs with the Stock Master app.

Insider holders

MDRX insider holders
InsiderRelationLatest transactionDateShares held
ALTMAN ELIZABETH ANNDirectorStock Award(Grant)Jun 26, 202235,552
GARRISON P GREGORYDirectorStock Award(Grant)Jun 26, 202260,569
HAMMOND LISAOfficerStock Award(Grant)Feb 25, 202470,416
JAMES THOMAS LANGANPresidentStock Award(Grant)Feb 25, 2024180,659
JONES LEAHChief Financial OfficerSaleSep 12, 202298,362
JUDGE JONATHAN JAMESDirectorStock Award(Grant)Jun 26, 2022132,487

Institution ownership

MDRX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.18.05%19,720,678248.48MJun 29, 2023
Vanguard Group Inc13.00%14,204,004178.97MJun 29, 2023
Dimensional Fund Advisors LP8.27%9,035,018113.84MJun 29, 2023
State Street Corporation3.69%4,034,00550.83MJun 29, 2023
Shaw D.E. & Co., Inc.3.49%3,816,65548.09MJun 29, 2023
William Blair Investment Management, LLC3.43%3,751,56747.27MJun 29, 2023

Fund ownership

MDRX fund ownership
Holder% heldSharesValueReported
iShares Core S&P Smallcap ETF6.75%7,376,95796.93MSep 29, 2023
Vanguard Total Stock Market Index Fund2.97%3,246,83940.91MJun 29, 2023
Vanguard Small-Cap Index Fund2.45%2,679,65933.76MJun 29, 2023
DFA U.S. Small Cap Value Series2.28%2,491,48433.68MJul 30, 2023
iShares Russell 2000 ETF2.28%2,494,90333.38MAug 30, 2023
Undiscovered Managers Behavioral Value Fund1.93%2,112,95426.62MJun 29, 2023
Advertisement